ADVB
Advanced Biomed Inc.
Next earnings Oct 6, 2026
$4.99
▲ +6.85%$4.99▼ -63.36%
over 1Y
L $3.71H $15.99
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+6.9%
1W+0.0%
1M+13.0%
3M+9.7%
YTD-17.4%
1Y-63.4%
Avoid
Conviction
Horizon
Long (>12mo)
Pre-revenue cancer-chip developer burning $5.8M/yr on $2.9M cash, priced ~31x book with 11 holders — dilution looms; avoid.
Revenue — · FY2025 & FY2024
ADVB is not yet a business — it is a clinical-stage microfluidic/CTC diagnostics developer with no reported revenue in either FY2024 or FY2025. The MD&A confirms the core products (A+Pre, AC-1000, A+CellScan, the immunostaining kits, A+LCGuard) are pre-commercial: A+LCGuard is a Class III device that 'is required to conduct clinical trials before completing the registration process,' with clinical research only planned to begin November 2025 and kit registrations merely 'submitted' in China. Revenue, approvals, and reimbursement are all in the future and unquantified in the data. With no top line, every profitability lens is negative by construction: net loss widened to -$3.26M (from -$2.78M), diluted EPS -$0.16, and ROE is -93.7% against a -$19.2M accumulated deficit.
Is ADVB a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread (caution)~90d expiry
- Long put 5 @ ~1.65 est
- Short put 4.5 @ ~1.33 est
debit $32max +$18max −$32BE 4.68
AVOID means we wouldn't engage at all — if expressing the short side anyway, only with capped risk.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY24 | FY25 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | — | — |
| Net income | -$2.78M | -$3.26M |
| Diluted EPS | -$0.14 | -$0.16 |
| Net margin | — | — |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$5.34M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-39.5%
FCF yield-71.0%
Quality & risk
ROIC (est.)—
Free cash flow-$5.86M
Total debt—
Net cash$2.90M
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has skewed negative — read the flagged items.
- 8-K Shareholder vote2026-07-01
Annual meeting held; shareholders voted on directors and routine proposals
- 8-K Material agreement2026-06-30
Entered new material definitive agreement; terms filed as exhibit
- DEF 14A Proxy statement2026-06-04
Proxy for annual meeting; board slate and routine governance proposals
- 10-Q Quarterly report2026-05-15
Q1 FY26: net losses and heavy cash burn persist; runway a concern
- 8-K Officer / director change2026-05-01
Closed asset acquisition/disposition with stock issuance and officer change
- 8-K Material agreement2026-04-14
Signed another material definitive agreement (partnership/financing)
- 8-K Material agreement2026-04-03
Entered material definitive agreement; exhibit filed
- 8-K Officer / director change2026-03-30
Executive/board change announced
- 10-Q Quarterly report2026-02-13
Quarterly loss continues amid ongoing pre-revenue cash burn
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-302026-07-01open ↗8-KPeriod ending 2026-06-302026-06-30open ↗DEF 14APeriod ending 2026-06-302026-06-04open ↗10-QPeriod ending 2026-03-312026-05-15open ↗8-KPeriod ending 2026-04-282026-05-01open ↗8-KPeriod ending 2026-04-132026-04-14open ↗8-KPeriod ending 2026-04-022026-04-03open ↗8-KPeriod ending 2026-03-252026-03-30open ↗8-KPeriod ending 2026-03-122026-03-16open ↗8-KPeriod ending 2026-02-202026-02-26open ↗10-QPeriod ending 2025-12-312026-02-13open ↗8-K/APeriod ending 2025-06-062026-02-10open ↗
Frequently asked
- Is Advanced Biomed Inc. (ADVB) a buy?
- ADVB currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Pre-revenue cancer-chip developer burning $5.8M/yr on $2.9M cash, priced ~31x book with 11 holders — dilution looms; avoid.
- What is Advanced Biomed Inc.'s quality score?
- ADVB scores 34.54759491941418/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001941029, latest 10-Q filed 2026-05-15) · EODHD · Proprietary analysis · as of 7/4/2026, 9:33:32 AM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 5:33 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.